Objective: Angiogenesis is necessary for tumor growth, invasion, and metastasis.
INTRODUCTION
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer patients and 14% of the cancer deaths [1] . Presently, 75,000 new patients of breast cancer occur in Indian women every year [2] .
Breast cancer can be separated mainly into two types Ductal carcinoma and Lobular carcinoma.Ductal carcinoma in situ is the proliferation of malignant epithelial cells confined to ducts, with no evidence of invasion through the basement membrane. Invasive ductal carcinoma (IDC) is the most common type of breast cancer. Invasive ductal carcinoma starts in a milk passage (duct) of the breast, breaks through the wall of the duct, and grows into the fatty tissue of the breast [3, 4] . Lobular carcinoma in situ refers to cancer cells that have formed in the milk glands and are still confined there. Invasive lobular carcinoma (ILC) starts in the milk-producing glands (lobules). Like IDC, it can spread (metastasize) to other parts of the body [5, 6] . Most studies divide breast cancer into four major molecular subtypes:Luminal A;Luminal B;Triple negative/basallike;HER2 type. . Luminal tumors have cells that look like those of breast cancers that start in the inner (luminal) cells lining the mammary ducts.Luminal A tumors tend to be:ER-positive and/or PR-positive,HER2-negative and Tumor grade 1 or 2, Luminal B tumors tend to be:ERpositive and/or PR-positive; Highly positive for Ki67 and/ or HER2-positive [7] .
Recent epidemiological data have shown a significant decline in breast cancer mortality over the past 15 years, as a result of screening programs, better education, and the introduction of more effective adjuvant treatments [8] . Unfortunately, about 25%-40% of patients eventually develop metastatic disease that, in spite of advances in treatment strategies, is still largely incurable. Results from experimental studies suggest that tumor progression and metastasis in breast cancer are angiogenesis dependent [9] .
A key mediator in neoangiogenesis is vascular endothelial growth factor (VEGF) as it stimulates endothelial cell proliferation and migration, and increases vascular permeability [10, 11] ; it is therefore regarded as a marker of tumour invasion and metastasis [12] . Overexpression of VEGF has been shown in various cancers [13] . Several polymorphisms in the VEGF gene have been reported to affect the expression of the gene [14] [15] [16] [17] .SNPs within the VEGF gene have been identified, some of which have functional significance. For example, the +405G>C polymorphisms in the 5'-untranslated region has a significant effect on VEGF protein expression [18] . G→C transition at +405 in the 5'-untranslated (5'-UTR) region has been implicated in a number of diseases, especially those with angiogenic basis [17, 19] . VEGF protein expression was found to be associated with +405 G>C polymorphism in controls [18] . Association has been reported in Breast cancer patient-control studies between VEGF polymorphisms and diseases such as diabetic retinopathy [17] , ovarian cancer [20] and endometriosis [21] .
A few studies [17, 22, 23] have reported that +405 G>C VEGF polymorphisms are associated with VEGF expression, but the results are inconsistent. Awata et al [17] reported that individuals with the +405 CC genotype had a higher fasting serum VEGF level than those with other genotypes, and that they carried an increased risk of diabetic retinopathy. On the other hand, Watson et al. [18] reported that the +405G allele is associated with higher lipopolysaccharide-stimulated VEGF expression by peripheral blood mononuclear cells than the +405C allele. Among Indians Suganthalakshmi et al. [24] found that the CG genotype was associated with retinopathy. Similarly Manjula et al [21] also reported that +405G allele in the 5'-UTR region of VEGF gene may influence the likelihood of a woman developing endometriosis.
In spite of the importance of angiogenesis in Breast cancer , there have been no published studies on the association of VEGF gene polymorphism and Breast cancer among Indians. In the present study, we investigated the relationship between +405G>C genetic polymorphism in the VEGF gene and the development of breast cancer.
MATERIALS AND METHODS

Patient Population
Histologically confirmed patients of Breast cancer samples were obtained from 200 patients registered (2008to2009) in the Breast service unit of Kidwai Memorial Institute of Oncology. Carcinomas included 96% invasive ductal and 4% invasive lobular types. Patient's age, stage, grade, nodal status, estrogen receptor(ER) and progesterone receptor (PR) status were noted from the case files. Age matched (+5 years) normal healthy females were selected as controls (200) . The study protocol was approved by the Institutional Ethical Committee and Informed consent was obtained from the patients/relatives of the subjects under study. All the participants of the study belonged to the same ethnic group.
The age limit for both populations was set at 21-81 years. The mean age for the cases was 48.80 ± 11.37 and for the control group was 47.29 ± 10.75 years. A preponderance of the patients was postmenopausal 73 (36.5%) and received no prior adjuvant therapy. Out of the 200 cases, 113 patients were node-positive and 87 cases were node-negative. Majority of the patients were in Stage II A followed by Stage III B. Most of the study subjects are in Grade III. Out of the 200 breast cancer cases, only 26 cases (13%) were showing distant metastasis.
Sample
About 5 ml of blood was collected from each subject after an overnight fast by routine venipuncture. The blood sample was then distributed into different tubes for the assays of various biochemical parameters.
DNA extraction DNA for PCR-RFLP analysis was extracted from leukocytes isolated from whole blood by using DNA extraction kit (Genei)
Genotyping of the VEGF polymorphism
Genotyping of the +405G>C polymorphisms in the 5' UTR of the VEGF gene was determined by PCR /RFLP analysis. The method described by Monika et al. [20] was used for the detection of +405G>C polymorphism. PCR was carried out in a total volume of 30 µl, containing 200 ng genomic DNA, 1.5µmol of each primer (Sigma,USA), IX Taq polymerase buffer (1.5mM MgCl2) and 1U of Taq DNA polymerase (Bangalore Genie, India). For the +405G>C polymorphism the forward and reverse primers were 5'-ATTTATTTTTGCTTGCCATT -3' and 5' -GTCTGTCTGTCTGTCCGTCA -3'respectively.PCR amplification was performed in a programmable thermal cycler gradient PCR system (Eppendorf AG, Hamburg, Germany). Genomic DNA was amplified in a final volume of 30 µl using the following conditions: Initial denaturation at 95 0 C for 5 min followed by 35 cycles at 94 0 C for 1 min, 57 0 C for 1.5 min and 72 0 C for 1 min. A final extension was at 72 0 C for 10 min. The PCR product was digested with the BsmFI restriction endonuclease. (New England Biolabs, USA) at 65°C overnight for the +405 G>C polymorphism, separated by 2% agarose gel electrophoresis, and identified using ethidium bromide staining. For the VEGF +405 polymorphism the uncut fragment was 304 bp (C allele) and digestion products were 193 and 111 bp (G allele).
Plasma VEGF
Plasma VEGF levels ranged from 11 to 876 pg/ml among breast cancer patients and a range of less than minimum detectable level (i.e. <9pg/ml) to 136.0 pg/ml among controls. The results we have got is similar to the result published by Rodreiguez et al [28] , who used a similar method for the detection of plasma VEGF.
Plasma is the preferred medium to measure VEGF levels, because a significant and highly variable platelet-mediated secretion of VEGF during the clotting process would invalidate the use of serum as an indicator of circulating VEGF levels in both controls. [29] Plasma VEGF levels were determined in 200 patients using commercially available enzyme-linked immunoassay (ELISA) designed to measure VEGF levels (Quantikine,R&D Systems Minneapolis, MN).The assay exhibits no significant cross-reactivity with other angiogenesis factors and has a sensitivity of 9.0 pg/ml. Optical density was measured at 450 nm using a microtitre plate reader (TECAN ELISA READER). A standard curve was prepared from 2000pg/ml stock standard VEGF by serially diluting as 31.2, 62.5,125,250,500,1000 with assay buffer and sample concentrations were determined.
ELISA
Aliquot 0.1ml per well of the 2000pg/ml, 1000pg/ml, 500pg/ ml, 250pg/ml, 125pg/ml, 62.5pg/ml, 31.2pg/ml human VEGF standard solutions into the precoated 96-well plate. Add 0.1ml of the sample diluent buffer into the control well (Zero well
Statistical Analysis
The data was analyzed using SPSS 16.0. The frequency of genotype was determined by direct counting. OR and 95% CI were estimated as a measure of association between the genotype and Breast cancer. The genotypic distribution amongst subjects was tested for Hardy-Weinberg equilibrium using Fisher's exact test. Results on continuous measurements are presented on Mean ± SD (Min-Max) and results on categorical measurements are presented in Number (%). Significance is assessed at 5 % level of significance. ROC curve analysis is performed to find the cut-off value VEGF-ELISA and Diagnostic value.
RESULTS
A preponderance of the patients were postmenopausal and received no prior adjuvant therapy. The median age of the patients was 48 years (range 25 -75 years). 73 patients were premenopausal, 127 patients were postmenopausal. Clinically healthy individuals were used as controls.
Genotype frequencies for the VEGF +405 SNPs are summarized in Table 1 . Amongst both patients and controls, the genotypic distributions of the individual SNPs as well as the VEGF allele system were all in Hardy-Weinberg equilibrium ( Table 2 ). The +405 Genotype frequencies amongst the 200 patients were GG=44.5%, GC=44% and CC=11.5%. The +405 Genotype frequencies amongst the 200 controls were GG=42.5%, GC=44.5% and CC=13%.
For the The presence of the 'C' allele abolishes the restriction site for BSMFI. For the VEGF+405 G>C polymorphism the uncut fragment was 304 bp (C allele) and digestion products were 193 and 111 bp (G allele). Heterozygous (405 GC ) will have 3 bands of 304 bp, 193bp and 111bp. Fig.1A Plasma VEGF levels ranged from 31 to 876 pg/ml among breast cancer patients and among controls a range of less than minimum detectable level, ie <9 pg/ml to 136.0 pg/ml . Statistical cut off was determined using ROC curve. (Fig.  2, Table 3 ). Mean VEGF level was significantly elevated in patients compared to control (t=8.248; P<0.001). The values are showed in Table 4 .
Baseline concentrations of plasma VEGF were elevated (that is, ≥ 123 pg/ml) in 52% (104) of the 200 evaluable patients and 48% patients were having low levels of VEGF(VEGF< 123 pg/ml). The Mean and SD values of VEGF were 126.58 pg/ml and 71.76±5.33 pg/ml for the patients and control group respectively. Next, we studied VEGF plasma levels and VEGF genotypes in Breast cancer patients and controls to assess possible functional relevance of the VEGF polymorphisms. The highest VEGF expression levels were observed within GG genotype, where as the lowest expression was observed within CC genotype (Table 5 ). Plasma VEGF levels correlated significantly with clinical stage of the disease (Table 6 ).
DISCUSSION
Angiogenesis is regulated by many growth factors, among which VEGF plays a central role and serves as an important prognostic factor in a variety of tumors, including breast cancers. The association of VEGF gene polymorphisms with disease risk attracts a great deal of attention because VEGF is one of the most potent angiogenic factors and plays a significant role in the development of solid tumors. Several studies have evaluated the association of VEGF polymorphisms with breast cancer risk [30] [31] [32] . The results, however, have been inconsistent.
Studies have shown that several polymorphisms were associated with the expression of the VEGF protein, and suggested that the regulation of VEGF expression occurs primarily at a transcriptional level [33] . The +405G>C polymorphism is characterized by a point mutation at position +405 of the VEGF gene that converts Guanine (G) to Cytosine (C). The +405G>C transition lies in 5'untransalted region of the VEGFgene [34] .Several transcription factor-binding sites are found in the VEGF5'-UTR region and transcriptional regulation of the gene is complex . Polymorphisms within the 5'-UTR region lead to differences in VEGF expression between individuals and could influence the etiology of a variety of pathological conditions with which VEGF has been associated [35] .
In our study we have found that VEGF levels were significantly increased (P<0.001) in patients compared to controls. The highest expression was observed for the GG genotype, and the lowest for CC genotype.
Watson et al. [18] reported that a G allele at position +405, which probably lies within the myeloid zinc finger protein (MZF1) binding site, affects transcriptional activity and increases VEGF expression in peripheral blood mononuclear cells in response to lipopolysaccharide. Furthermore, the +405G haplotype has been associated with higher promoter activity, and therefore higher VEGF expression, than the +405C haplotype [36] . We also observed that the +405C haplotype, which is associated with lower promoter activity, was more common in controls than in affected women.
In contrast Awata et al [12] reported that individuals with the +405 CC genotype had a higher fasting serum VEGF level than those with other genotypes, and that they carried an increased risk of diabetic retinopathy. Stevens et al, [29] also reported that haplotype +405G has a higher promoter activity than haplotype+405C. In a study of more than 1,000 women with all stages of breast cancer, Lu et al [30] found that the +405G>C polymorphism was significantly associated with survival, with the+405C/C genotype having the best survival. Multiple factors could be the reason for the difference between our observations in this study and results reported by others. Those include differences in ethnicity, gene-gene interaction and gene environment interaction.
Plasma VEGF levels ranged from 36 to 537 pg/ml among breast cancer patients and a range of less than minimum detectable level to <min to 132.0 pg/ml among controls. The authors found that increased plasma VEGF levels were significantly associated with, clinical stage of disease. So detection of plasma VEGF may be helpful for selecting the patients who may benefit from validated anti-VEGF treatments. This finding agrees with that of Salven et al [31] who showed a correlation between circulating levels of VEGF and the stage of disease or tumor burden.
SUMMARY
Since all the three VEGF genotypes (GG, GC&CC) were showing an increased plasma VEGF levels, our study did not prove that mutant CC genotype is associated with higher VEGF expression. The authors found that increased plasma VEGF levels were significantly associated with, clinical stage of disease. So detection of plasma VEGF may be helpful for selecting the patients who may benefit from validated anti-VEGF treatments. Further studies on larger populations may be necessary to confirm these observations. +405G>C variant may contribute to a modest increase in risk. Other genetic variants and non genetic factors such as age, ER/PR status, stage, and plasma VEGF levels can modify the risk contributed by the variants. 
